Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the International Prognostic Scoring System (IPSS) as low risk or intermediate-1 risk and with a deletion 5q...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Giagounidis, Aristoteles, Fenaux, Pierre, Mufti, Ghulam J., Muus, Petra, Platzbecker, Uwe, Sanz, Guillermo, Cripe, Larry, Von Lilienfeld-Toal, Marie, Wells, Richard A.
Формат: Artigo
Язык:Inglês
Опубликовано: Springer-Verlag 2008
Предметы:
Review Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2275303/
https://ncbi.nlm.nih.gov/pubmed/18265982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-008-0449-0
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы